help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on July 17, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0620
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/10/3844    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zitzmann, M.
Right arrow Articles by Nieschlag, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zitzmann, M.
Right arrow Articles by Nieschlag, E.
Related Collections
Right arrow Neuroendocrinology and Pituitary

Submitted on March 20, 2007
Accepted on July 9, 2007

Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men

Michael Zitzmann and Eberhard Nieschlag*

Institute of Reproductive Medicine, University Clinics, Muenster, Germany

* To whom correspondence should be addressed. E-mail: Eberhard.Nieschlag{at}ukmuenster.de.

Context. A reliable form of androgen substitution therapy regarding kinetics, tolerance and restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the long-acting ester testosterone undecanoate (TU) offers a new modality.

Objective. To assess safety of TU regarding metabolic and pharmacogenetic confounders.

Design. Longitudinal one-arm open observation trial. A minimum of 5 individual assessments was a prerequisite. Putative modulators of safety parameters entering regression models were: nadir and/or delta total testosterone concentrations, body mass index (BMI), androgen receptor (AR) gene CAG repeat length and age.

Setting. Andrological outpatient clinic.

Patients. 66 hypogonadal men, mean age 38 ± 9.9 years.

Main outcome measures. 515 data time points each related to prostate, erythropoeisis, lipoproteins and circulation during 118 treatment-years with 1000 mg TU at 10 to 14-week intervals.

Results. Testosterone substitution resulted in significant decrements of serum levels of LDL- cholesterol, resting diastolic and systolic blood pressure and heart rate. Erythropoeisis was stimulated and concentrations of HDL-cholesterol increased. Parameters remained stable after 4 injections. No adverse effects regarding the prostate were observed. Significantly increased hematocrit > 50% was predicted by enhanced androgen action (shorter AR CAG repeats/higher testosterone levels). However, also insufficient androgen action (longer AR CAG repeats/lower testosterone levels) caused pathological safety parameters (high blood pressure, adverse lipid profiles). In addition, a BMI ≥ 30 kg x m-2 represents a clinically relevant factor for the occurrence of all pathological safety parameters. Risk calculations for obese patients and non-linear pharmacogenetic models to tailor androgen substitution are presented.

Conclusions. Testosterone substitution with intramuscular TU is generally well tolerated. Modifications of androgen action are due to both AR CAG repeats and testosterone levels. Adverse observations are mostly seen in obese patients.


Key words: Testosterone • hypogonadism • safety • obesity • pharmacogenetics • androgen receptor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society